The molecular basis of selectivity between CC and CXC chemokines: the possibility of chemokine antagonists as anti-inflammatory agents.
Geneva Biomedical Research Institute, Glaxo-Wellcome Research and Development S.A., Switzerland.
T N
TN
Wells
M
M
Lusti-Narasimhan
C W
CW
Chung
R
R
Cooke
C A
CA
Power
M C
MC
Peitsch
A E
AE
Proudfoot
D000595:Amino Acid Sequence; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D018925:Chemokines / Q000502:physiology*; D016209:Interleukin-8 / Q000235:genetics / Q000378:metabolism; D008958:Models, Molecular; D008969:Molecular Sequence Data; D009504:Neutrophils / Q000378:metabolism; D011487:Protein Conformation; D018123:Receptors, Interleukin / Q000037:antagonists & inhibitors / Q000378:metabolism; D023062:Receptors, Interleukin-8A; D023063:Receptors, Interleukin-8B; D013329:Structure-Activity Relationship; D013379:Substrate Specificity
D015703:Antigens, CD; D018925:Chemokines; D016209:Interleukin-8; D018123:Receptors, Interleukin; D023062:Receptors, Interleukin-8A; D023063:Receptors, Interleukin-8B